Aptevo Therapeutics Inc APVO shares are trading higher Thursday after the company reported 2021 financial results.
Aptevo said royalty revenue totaled $12.3 million in 2021, up from royalties of $4.3 million in 2020. The company reported a net loss of $28.5 million or $6.07 per share, which was worse than the net loss of $17.8 million or $5.23 per share during the prior year.
Aptevo said it had cash and cash equivalents of $46.3 million at the end of 2021.
Aptevo is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics for the treatment of different forms of cancer.
See Also: Why Ampio Pharmaceuticals Stock Is Rising Today
APVO 52-Week Range: $4.40 - $32.57
The stock was up 25.2% at $6.56 at publication time.
Photo: Belova59 from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.